Albumin–lipid NPs consisting of medium-chain triglycerides and a lactobionic acid–human serum albumin conjugate were developed by Dayani et al., 2022 as a targeted drug-delivery system of Sorafenib for the treatment of hepatocellular carcinoma [15]. The gene discussed is ALB; the disease is hepatocellular carcinoma.